Faron to acquire AOC3 antagonist platform
Faron Pharmaceuticals Oy ("Faron" or the "Company") Faron to acquire AOC3 antagonist platform technology Company announcement, 02 March 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that it has acquired rights for the potential new use of AOC3 inhibitors ("Agreement") covered by a recently filed patent application ("Invention"). The AOC3 enzymatic domain, a semicarbazide-sensitive amine oxidase is known to produce hydrogen peroxide, a